Skip to main content

Black Diamond Therapeutics, Inc 10-Q for FY2026 Q3

Black Diamond Therapeutics, Inc. (BDTX)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Black Diamond Therapeutics, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Black Diamond Therapeutics plans a global Phase 3 silevertinib trial in approximately 300 frontline EGFR-NCM NSCLC patients with brain metastases, targeting initiation in the second quarter of 2027. Phase 2 median progression-free survival was 15.0 months among 43 frontline patients. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $0 a year earlier
Net loss
$10.01M
compared with a net loss of $8.5M a year earlier
Diluted EPS
-$0.17
compared with -$0.15 a year earlier